ECO Animal Health Group (LON:EAH) Stock Price Passes Above 50-Day Moving Average – Here’s Why

ECO Animal Health Group plc (LON:EAH)’s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of GBX 105.69 and traded as high as GBX 113. ECO Animal Health Group shares last traded at GBX 112.45, with a volume of 20,448 shares changing hands.

Wall Street Analysts Forecast Growth

Separately, Shore Capital boosted their price objective on ECO Animal Health Group from GBX 150 to GBX 160 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. One research analyst has rated the stock with a Buy rating, According to MarketBeat, ECO Animal Health Group currently has a consensus rating of “Buy” and a consensus price target of GBX 160.

ECO Animal Health Group Price Performance

The company has a quick ratio of 2.14, a current ratio of 2.96 and a debt-to-equity ratio of 4.81. The stock has a market cap of £75.44 million, a price-to-earnings ratio of 25.62 and a beta of -0.05. The company’s 50-day moving average is GBX 105.69 and its 200-day moving average is GBX 90.36.

ECO Animal Health Group (LON:EAH) last released its quarterly earnings data on Monday, December 1st. The company reported GBX (0.54) earnings per share for the quarter. ECO Animal Health Group had a net margin of 1.17% and a return on equity of 1.27%.

Insider Buying and Selling

In related news, insider David Hallas purchased 18,348 shares of the stock in a transaction on Thursday, December 4th. The shares were purchased at an average cost of GBX 109 per share, for a total transaction of £19,999.32. 11.17% of the stock is currently owned by corporate insiders.

ECO Animal Health Group Company Profile

ECO Animal Health is a world leader in animal health, developing and marketing branded veterinary pharmaceuticals globally, with expertise in antibiotics and vaccines for pigs and poultry. We have a maturing proprietary R&D pipeline.

Headquartered in the UK, with global offices including R&D and manufacturing, we have marketing authorisations in over 70 countries and employ over 200 people worldwide.

Our lead product, Aivlosin® is a proprietary, patented medication which is effective against both respiratory and intestinal diseases in pigs and poultry.